Dietary RRR-a-tocopherol succinate attenuates lipopolysaccharide-inducedinflammatory cytokines secretion in broiler chicks
2010-12-281471
The anti-inflammatory effects of two esters of a-tocopherol (a-TOH), all-rac-a-TOH acetate (DL-a-TOA) and RRR-a-TOH succinate (D-a-TOS),
on broilers repeatedly challenged with lipopolysaccharide (LPS) were investigated. Three hundred and twenty 1-d-old broiler chicks were allottedinto four treatment groups and fed on a control diet (30 mg/kg DL-a-TOA) or diets containing 10, 30, 50 mg/kg D-a-TOS. Half of the birds fromeach treatment group were challenged with 0·9% NaCl solution or LPS (250 mg/kg body weight) at16,18and20dofage.Theresultsindicated
that the pretreatment of birds with 50 mg/kg D-a-TOS markedly reduced serum PGE2 secretion and increased the concentrations of serum or hepatica-TOH. When LPS-challenged birds were pretreated with 30 or 50 mg/kg D-a-TOS, the increases of plasma and splenic concentrations of interferon-g, IL-1b, IL-2, IL-6, IL-4 and IL-10 were dramatically attenuated. Also, a significant decrease of hepatic reactive oxygen species (ROS) andhepatic or splenic phosphokinase C (PKC) activities was found in birds pretreated with 30 or 50 mg/kg D-a-TOS. Furthermore, D-a-TOS inhibitedthe activation of NF-kB by preventing the degradation of inhibitory-kBa. In conclusion, D-a-TOS is able to prevent LPS-induced inflammationresponse in vivo. The beneficial effect may depend on suppressing the secretion of various plasma and splenic inflammatory mediators throughinhibiting NF-kB activation and by blocking ROS signalling, in which PKC may play an assistant role.
RRR-a-tocopherol succinate: Cytokines: Inflammatory response: NF-kB
on broilers repeatedly challenged with lipopolysaccharide (LPS) were investigated. Three hundred and twenty 1-d-old broiler chicks were allottedinto four treatment groups and fed on a control diet (30 mg/kg DL-a-TOA) or diets containing 10, 30, 50 mg/kg D-a-TOS. Half of the birds fromeach treatment group were challenged with 0·9% NaCl solution or LPS (250 mg/kg body weight) at16,18and20dofage.Theresultsindicated
that the pretreatment of birds with 50 mg/kg D-a-TOS markedly reduced serum PGE2 secretion and increased the concentrations of serum or hepatica-TOH. When LPS-challenged birds were pretreated with 30 or 50 mg/kg D-a-TOS, the increases of plasma and splenic concentrations of interferon-g, IL-1b, IL-2, IL-6, IL-4 and IL-10 were dramatically attenuated. Also, a significant decrease of hepatic reactive oxygen species (ROS) andhepatic or splenic phosphokinase C (PKC) activities was found in birds pretreated with 30 or 50 mg/kg D-a-TOS. Furthermore, D-a-TOS inhibitedthe activation of NF-kB by preventing the degradation of inhibitory-kBa. In conclusion, D-a-TOS is able to prevent LPS-induced inflammationresponse in vivo. The beneficial effect may depend on suppressing the secretion of various plasma and splenic inflammatory mediators throughinhibiting NF-kB activation and by blocking ROS signalling, in which PKC may play an assistant role.
RRR-a-tocopherol succinate: Cytokines: Inflammatory response: NF-kB
